Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Manufacturing Problems Aren't Rising, But It Was A Hot July

Executive Summary

Lack of readiness derails eye drugs from Valeant and Ocular, which now must convince FDA they know what they are making; meanwhile, an expert shares how mistake-proofing processes can help.

Advertisement

Related Content

Roche’s Highly Anticipated Ocrelizumab Delayed By Manufacturing Issues
Keeping Track: Novartis, Calardius Pick Up Speed; ADMA Stumbles
FDA, Industry Call For Human Factors Approaches To Assuring Data Integrity
‘Complete Response’ Letters
FDA Advises Starting With the Lab When Sniffing Out Data Integrity

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118862

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel